Feng et al. found that cholesterol‐induced leucine aminopeptidase 3 (LAP3) could serve as a potential novel candidate biomarker for the diagnosis of nonalcoholic fatty liver disease.12 Here, LAP3 is linked to metabolic dysfunction-associated steatotic liver disease.